PharmAust (ASX:PAA) has announced its lead drug candidate monepantel (MPL) has shown minimal side effects and an increase in survival time, in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs.
The clinical-stage biotechnology company developing therapeutics for both humans and animals says one dog surpassed 240 days with stable disease and continued excellent Quality of Life (QoL).
It says the drug is a novel, potent, and safe inhibitor of the mTOR pathway—a pathway having key influences in cancer growth and neurodegenerative diseases.
PharmAust is also recruiting pet dogs with B-cell lymphoma to complete the Phase 2 evaluation and require 8 of a further 20 dogs to meet Bayesian outcomes for a successful Phase 2 trial.